arrow_back Back to App

Temporary Financial Support for Long-Term Care Pharmacies to Ensure Patient Access.

This bill introduces a temporary supply fee (starting at $30 in 2026) paid by Medicare Part D plans to long-term care pharmacies. The goal is to stabilize the finances of these specialized pharmacies, ensuring that patients in long-term care facilities maintain uninterrupted access to necessary medications and services. The federal government will fully reimburse the insurance plans for these fees.
Key points
Long-term care pharmacies will receive an extra fee for dispensing specific drugs to Medicare patients during 2026 and 2027.
The change is designed to protect patient access to medications in long-term care settings, particularly following the implementation of new drug price negotiation rules.
The government mandates a study to assess the long-term financial health of these pharmacies and recommend sustainable payment solutions.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_5031
Sponsor: Rep. Van Duyne, Beth [R-TX-24]
Process start date: 2025-08-22
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Preserving Patient Access to Long-Term Care Pharmacies Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_5031.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-08-22.

What are the main provisions?

Key points include:

  • Long-term care pharmacies will receive an extra fee for dispensing specific drugs to Medicare patients during 2026 and 2027.
  • The change is designed to protect patient access to medications in long-term care settings, particularly following the implementation of new drug price negotiation rules.
  • The government mandates a study to assess the long-term financial health of these pharmacies and recommend sustainable payment solutions.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Van Duyne, Beth [R-TX-24].

What is the latest detailed status?

The latest detailed status is: Introduced in House

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-31.

CATEGORIES

Health Benefits